Announced details
Recurrent meningioma, particularly treatment with BNCT. The clinical trial enrolled patients with recurrent high-grade meningioma (WHO grade 2 or 3).
Median progression-free survival: 14.4 months in the investigational treatment group receiving BNCT versus 1.4 months in the control group. The difference was statistically significant.
The results of the physician-initiated clinical trial conducted at Osaka Medical and Pharmaceutical University, among other information, formed the basis for the application for approval.
Institution conducting the physician-initiated clinical trial. Other details, including location, representative, business activities, capital and year established, are Not disclosed.
Designation as an orphan drug; priority review product
The impact on results for the fiscal year ending March 2027 is expected to be minor. Over the medium to long term, the company expects this to contribute to growth in its BNCT business.
The company does not address Contract Value / Offering price.
Physician-initiated clinical trial (Phase II randomized controlled trial); support from the Japan Agency for Medical Research and Development (AMED)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Steboronin® intravenous infusion bag 9,000 mg/300 mL; boron neutron capture therapy (BNCT) |
| Counterparty | Osaka Medical and Pharmaceutical University |
| Counterparty overview | Institution conducting the physician-initiated clinical trial. Other details, including location, representative, business activities, capital and year established, are Not disclosed. |
| Relationship with the Company | The results of the physician-initiated clinical trial conducted at Osaka Medical and Pharmaceutical University, among other information, formed the basis for the application for approval. |
| Launch date | Reimbursement coverage is expected to begin on 1 March 2027. |
| Applicable area | Recurrent meningioma, particularly treatment with BNCT. The clinical trial enrolled patients with recurrent high-grade meningioma (WHO grade 2 or 3). |
| Award/certification name | Designation as an orphan drug; priority review product |
| Quantitative Effects | Median progression-free survival: 14.4 months in the investigational treatment group receiving BNCT versus 1.4 months in the control group. The difference was statistically significant. |
| Impact on Business Performance | The impact on results for the fiscal year ending March 2027 is expected to be minor. Over the medium to long term, the company expects this to contribute to growth in its BNCT business. |
| Source | Physician-initiated clinical trial (Phase II randomized controlled trial); support from the Japan Agency for Medical Research and Development (AMED) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Recurrent meningioma can be difficult to treat with repeat surgery or re-irradiation, and treatment options had been limited because no drug therapy had previously been approved in Japan. The approval was also based on the statistically significant difference observed in a physician-initiated clinical trial, in which median progression-free survival was 14.4 months in the BNCT group versus 1.4 months in the control group.